ClinicalTrials.gov
public full text
Public Domain
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia#1046781
- Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia#992060
- CD7 CAR-T Cells in T-cell Lymphoma/Leukemia#1010227
- Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies#1058634
- CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)#321709
Record · ID 838986
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive